Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka)

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Ladda ner Bipacksedel (PIL)
17-12-2021
Ladda ner Produktens egenskaper (SPC)
17-12-2021

Aktiva substanser:

lenalidomide hydrochloride monohydrate

Tillgänglig från:

Krka, d.d., Novo mesto 

ATC-kod:

L04AX04

INN (International namn):

lenalidomide

Terapeutisk grupp:

Immunosuppressants

Terapiområde:

Multiple Myeloma; Lymphoma, Follicular

Terapeutiska indikationer:

Multiple myelomaLenalidomide krka d.d. Novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide krka d.d. Novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide krka d.d. Novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Follicular lymphomaLenalidomide krka d.d. Novo mesto in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).Multiple myelomaLenalidomide krka d.d. Novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide krka d.d. Novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide krka d.d. Novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Follicular lymphomaLenalidomide krka d.d. Novo mesto in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).

Produktsammanfattning:

Revision: 3

Bemyndigande status:

Authorised

Tillstånd datum:

2021-02-11

Bipacksedel

                                79
B. PACKAGE LEAFLET
80
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
LENALIDOMIDE KRKA D.D. NOVO MESTO 2.5 MG HARD CAPSULES
LENALIDOMIDE KRKA D.D. NOVO MESTO 5 MG HARD CAPSULES
LENALIDOMIDE KRKA D.D. NOVO MESTO 7.5 MG HARD CAPSULES
LENALIDOMIDE KRKA D.D. NOVO MESTO 10 MG HARD CAPSULES
LENALIDOMIDE KRKA D.D. NOVO MESTO 15 MG HARD CAPSULES
LENALIDOMIDE KRKA D.D. NOVO MESTO 20 MG HARD CAPSULES
LENALIDOMIDE KRKA D.D. NOVO MESTO 25 MG HARD CAPSULES
lenalidomide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Lenalidomide Krka d.d. Novo mesto is and what it is used for
2.
What you need to know before you take Lenalidomide Krka d.d. Novo
mesto
3.
How to take Lenalidomide Krka d.d. Novo mesto
4.
Possible side effects
5.
How to store Lenalidomide Krka d.d. Novo mesto
6.
Contents of the pack and other information
1.
WHAT LENALIDOMIDE KRKA D.D. NOVO MESTO IS AND WHAT IT IS USED FOR
WHAT LENALIDOMIDE KRKA D.D. NOVO MESTO IS
Lenalidomide Krka d.d. Novo mesto contains the active substance
‘lenalidomide’. This medicine
belongs to a group of medicines which affect how your immune system
works.
WHAT LENALIDOMIDE KRKA D.D. NOVO MESTO IS USED FOR
Lenalidomide Krka d.d. Novo mesto is used in adults for:
-
Multiple myeloma
-
Follicular lymphoma
MULTIPLE MYELOMA
Multiple myeloma is a type of cancer which affects a certain kind of
white blood cell, called the
plasma cell. These cells collect in the bone marrow and divide,
becoming out of control. This can
damage the bones and kidneys.
Multiple myeloma generally c
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Lenalidomide Krka d.d. Novo mesto 2.5 mg hard capsules
Lenalidomide Krka d.d. Novo mesto 5 mg hard capsules
Lenalidomide Krka d.d. Novo mesto 7.5 mg hard capsules
Lenalidomide Krka d.d. Novo mesto 10 mg hard capsules
Lenalidomide Krka d.d. Novo mesto 15 mg hard capsules
Lenalidomide Krka d.d. Novo mesto 20 mg hard capsules
Lenalidomide Krka d.d. Novo mesto 25 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each hard capsule contains lenalidomide hydrochloride monohydrate
equivalent to 2.5 mg, 5 mg,
7.5 mg, 10 mg, 15 mg, 20 mg or 25 mg lenalidomide.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule (capsule)
Lenalidomide Krka d.d. Novo mesto 2.5 mg hard capsules
Capsule cap is green, capsule body is green with imprinted black mark
2.5. Capsule content is white to
yellow white or to brown white powder. Hard capsule size: 4, length 14
± 1 mm.
Lenalidomide Krka d.d. Novo mesto 5 mg hard capsules
Capsule cap is blue, capsule body is blue with imprinted black mark 5.
Capsule content is white to
yellow white or to brown white powder. Hard capsule size: 2, length 18
± 1 mm.
Lenalidomide Krka d.d. Novo mesto 7.5 mg hard capsules
Capsule cap is brown, capsule body is brown with imprinted white mark
7.5. Capsule content is white
to yellow white or to brown white powder. Hard capsule size: 1, length
19 ± 1 mm.
Lenalidomide Krka d.d. Novo mesto 10 mg hard capsules
Capsule cap is green, capsule body is brown with imprinted white mark
10. Capsule content is white to
yellow white or to brown white powder. Hard capsule size: 0, length 21
± 1 mm.
Lenalidomide Krka d.d. Novo mesto 15 mg hard capsules
Capsule cap is brown, capsule body is blue with imprinted black mark
15. Capsule content is white to
yellow white or to brown white powder. Hard capsule size: 2, length 18
± 1 mm.
Lenalidomide Krka d.d. Novo mesto 20 mg hard capsules
Capsule cap is green, capsule body is blue with imprinted black mark
20
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 17-12-2021
Produktens egenskaper Produktens egenskaper bulgariska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 31-08-2021
Bipacksedel Bipacksedel spanska 17-12-2021
Produktens egenskaper Produktens egenskaper spanska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 31-08-2021
Bipacksedel Bipacksedel tjeckiska 17-12-2021
Produktens egenskaper Produktens egenskaper tjeckiska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 31-08-2021
Bipacksedel Bipacksedel danska 17-12-2021
Produktens egenskaper Produktens egenskaper danska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 31-08-2021
Bipacksedel Bipacksedel tyska 17-12-2021
Produktens egenskaper Produktens egenskaper tyska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 31-08-2021
Bipacksedel Bipacksedel estniska 17-12-2021
Produktens egenskaper Produktens egenskaper estniska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 31-08-2021
Bipacksedel Bipacksedel grekiska 17-12-2021
Produktens egenskaper Produktens egenskaper grekiska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 31-08-2021
Bipacksedel Bipacksedel franska 17-12-2021
Produktens egenskaper Produktens egenskaper franska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 31-08-2021
Bipacksedel Bipacksedel italienska 17-12-2021
Produktens egenskaper Produktens egenskaper italienska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 31-08-2021
Bipacksedel Bipacksedel lettiska 17-12-2021
Produktens egenskaper Produktens egenskaper lettiska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 31-08-2021
Bipacksedel Bipacksedel litauiska 17-12-2021
Produktens egenskaper Produktens egenskaper litauiska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 31-08-2021
Bipacksedel Bipacksedel ungerska 17-12-2021
Produktens egenskaper Produktens egenskaper ungerska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 31-08-2021
Bipacksedel Bipacksedel maltesiska 17-12-2021
Produktens egenskaper Produktens egenskaper maltesiska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 31-08-2021
Bipacksedel Bipacksedel nederländska 17-12-2021
Produktens egenskaper Produktens egenskaper nederländska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 31-08-2021
Bipacksedel Bipacksedel polska 17-12-2021
Produktens egenskaper Produktens egenskaper polska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 31-08-2021
Bipacksedel Bipacksedel portugisiska 17-12-2021
Produktens egenskaper Produktens egenskaper portugisiska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 31-08-2021
Bipacksedel Bipacksedel rumänska 17-12-2021
Produktens egenskaper Produktens egenskaper rumänska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 31-08-2021
Bipacksedel Bipacksedel slovakiska 17-12-2021
Produktens egenskaper Produktens egenskaper slovakiska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 31-08-2021
Bipacksedel Bipacksedel slovenska 17-12-2021
Produktens egenskaper Produktens egenskaper slovenska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 31-08-2021
Bipacksedel Bipacksedel finska 17-12-2021
Produktens egenskaper Produktens egenskaper finska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 31-08-2021
Bipacksedel Bipacksedel svenska 17-12-2021
Produktens egenskaper Produktens egenskaper svenska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 31-08-2021
Bipacksedel Bipacksedel norska 17-12-2021
Produktens egenskaper Produktens egenskaper norska 17-12-2021
Bipacksedel Bipacksedel isländska 17-12-2021
Produktens egenskaper Produktens egenskaper isländska 17-12-2021
Bipacksedel Bipacksedel kroatiska 17-12-2021
Produktens egenskaper Produktens egenskaper kroatiska 17-12-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 31-08-2021

Sök varningar relaterade till denna produkt